SanFran, no reason to bring up Bioasis/BTI. There's an entirely different Agoracom board dor that. Keep it on topic please.

I agree with KayackerBC that any new statements can't be based on results from the blinded, incomplete BETonMACE trial. Any suggestion otherwise is simply ridiculous.

As for the statement in the revised website "Patients who take apabetalone have fewer heart attacks, strokes and cardiac-related deaths," that is over-reaching. In the combined ASSURE/SUSTAIN post-hoc analysis there were only 8 and 3 total 3-point MACE events in the total and diabetic groups, respectively. I broke it down here, and you can also see a similar breakdown in the Atherosclerosis 2016 paper. In my opinion this new statement on the website is premature and WAY underpowered (assuming it is based on post-hoc).

SanFran stated "What if top line results are available? We are in the potential zone for that.   No one can rule that out." Yes, we can rule that out. Guidance is that after hitting 250 events that adjudication and follow up will take 2-3 months with top-line shortly thereafter. They are still dosing and waiting to hit 250 events. Re-visit the AGM and BIO Europe slide decks, the most recent MD&A or the latest Zacks report if you need a refresher.

BearDownAZ